Candriam Luxembourg S.C.A. Buys 11,256 Shares of REDHILL BIOPHAR/S (NASDAQ:RDHL)
Candriam Luxembourg S.C.A. increased its holdings in REDHILL BIOPHAR/S (NASDAQ:RDHL) by 15.8% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 82,523 shares of the biotechnology company’s stock after purchasing an additional 11,256 shares during the period. Candriam Luxembourg S.C.A.’s holdings in REDHILL BIOPHAR/S were worth $553,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. D.A. Davidson & CO. bought a new stake in REDHILL BIOPHAR/S in the 1st quarter worth about $50,000. Meitav Dash Investments Ltd. bought a new stake in REDHILL BIOPHAR/S in the 1st quarter worth about $57,000. Jane Street Group LLC bought a new stake in REDHILL BIOPHAR/S in the 1st quarter worth about $95,000. Schonfeld Strategic Advisors LLC bought a new stake in REDHILL BIOPHAR/S in the 4th quarter worth about $104,000. Finally, Parametric Portfolio Associates LLC increased its holdings in REDHILL BIOPHAR/S by 121.2% in the 1st quarter. Parametric Portfolio Associates LLC now owns 24,904 shares of the biotechnology company’s stock worth $113,000 after buying an additional 13,647 shares in the last quarter. Institutional investors own 17.55% of the company’s stock.
Several equities research analysts recently commented on RDHL shares. BidaskClub upgraded REDHILL BIOPHAR/S from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Zacks Investment Research downgraded REDHILL BIOPHAR/S from a “hold” rating to a “strong sell” rating in a report on Wednesday. Finally, ValuEngine cut REDHILL BIOPHAR/S from a “buy” rating to a “hold” rating in a research report on Saturday.
REDHILL BIOPHAR/S (NASDAQ:RDHL) last announced its earnings results on Wednesday, May 27th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.12). The firm had revenue of $1.06 million during the quarter, compared to analysts’ expectations of $3.79 million. REDHILL BIOPHAR/S had a negative return on equity of 125.23% and a negative net margin of 883.97%. As a group, equities analysts forecast that REDHILL BIOPHAR/S will post -0.68 earnings per share for the current fiscal year.
About REDHILL BIOPHAR/S
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.
Read More: Balanced Fund
Want to see what other hedge funds are holding RDHL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REDHILL BIOPHAR/S (NASDAQ:RDHL).
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.